News Conference News ACC 2024 Need a Statin for Primary Prevention? There’s an App for That Michael O'Riordan April 10, 2024
News Conference News ACC 2024 Oral Device Noninferior to CPAP for Reducing BP in Sleep Apnea: CRESCENT Caitlin E. Cox April 06, 2024
News Conference News ACC 2024 Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT Todd Neale March 27, 2024
News Daily News High-Risk ‘Clues’ Add Heft to Calcium Scores in Primary Prevention Michael O'Riordan February 29, 2024
News Daily News Living Near Bars, Restaurants Linked to Greater Likelihood of HF L.A. McKeown February 29, 2024
News Daily News High Lp(a) Levels Harmful in Patients With and Without ASCVD Michael O'Riordan February 27, 2024
News Daily News Niacin, When Broken Down by the Body, Can Spur Inflammation Caitlin E. Cox February 22, 2024
News Daily News High-Protein Diets Linked to Amino Acid Activation of ASCVD Pathway L.A. McKeown February 21, 2024
News Daily News Increased Lp(a) Ups CV Risk Regardless of hs-CRP Level Yael L. Maxwell February 15, 2024
News Daily News Salt Substitute Slashes New Hypertension Diagnoses: DECIDE-Salt L.A. McKeown February 14, 2024
News Daily News Low Bleeding Profile With Asundexian Seen in Pooled Analysis L.A. McKeown February 13, 2024
News Daily News Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER Michael O'Riordan February 08, 2024
News Daily News Universal Risk Tool Works Well in Both Primary and Secondary Prevention Michael O'Riordan February 01, 2024
News Daily News Less Is More: Lp(a) Much More Atherogenic Than LDL Michael O'Riordan January 16, 2024
News Daily News Diagnosing FH in Kids and Teens Should Happen Early: In Real Life, It Varies Michael O'Riordan December 19, 2023
News Daily News Who Benefits Most From Semaglutide and How Long Will That Take? Shelley Wood December 19, 2023
News Daily News Millions of Lives Lost to CVD Each Year: ‘Almanac’ Updates Global Burden Caitlin E. Cox December 12, 2023
News Daily News Family History of CVD? Low PUFA Intake May Add to Risk Michael O'Riordan December 12, 2023